MannKind Corporation (MNKD)
MNKD moved a median of -0.25% 30 minutes after news, and -0.92% by the close. How MNKD actually reacts to news — the realized, point-in-time move the market made, measured across 335 labeled events over the last three years with zero look-ahead.
MNKD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 335 |
| 30-min | -0.25% | 43% | 335 |
| 60-min | -0.14% | 48% | 335 |
| to close | -0.92% | 41% | 333 |
| Middle 50% of MNKD reactions | -1.68% to +1.14% |
|---|---|
| Median reaction (30-min) | -0.25% |
| Measured reactions | 335 |
Half of all MannKind Corporation news events land between -1.68% and +1.14% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MNKD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 16 | -0.49% | 38% | -0.09% |
| Analyst downgrades | 11 | -0.74% | 36% | -1.42% |
| Coverage initiations | 24 | +0.28% | 50% | +1.66% |
| Rating reiterations | 51 | +0.58% | 59% | +0.62% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how MNKD ranks against every other measured name →
That’s how MNKD usually reacts — get an email when it moves on news →Email me when MNKD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MNKD's baseline. Nothing else.
Recent MNKD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) | Press release | GlobeNewswire | -0.77% | -3.99% | |
| MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Press release | GlobeNewswire | +0.84% | -5.29% | |
| MannKind to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +1.75% | +1.00% | |
| Form 8-K MANNKIND CORP For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.97% | |
| Form 10-Q MANNKIND CORP For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.79% | +2.10% | |
| Form 8-K MANNKIND CORP For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | +2.10% | |
| MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.79% | +2.10% | |
| MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF | Press release | GlobeNewswire | +0.00% | -1.28% | |
| MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026 | Press release | GlobeNewswire | +0.00% | -1.28% | |
| Form 8-K MANNKIND CORP For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | -5.95% | |
| MannKind Announces $50 Million Private Placement | Press release | GlobeNewswire | -0.46% | +1.98% | |
| MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease | Press release | GlobeNewswire | -0.46% | +1.98% | |
| MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D | Press release | GlobeNewswire | +0.65% | +1.81% | |
| Data at ADA 2026 Highlights Key Findings from Clinical and Real-World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems | Press release | GlobeNewswire | +0.29% | -2.31% | |
| MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF | Press release | GlobeNewswire | -1.17% | -2.04% | |
| Form 8-K MANNKIND CORP For: May 29 | SEC filing · Form 8-K | SEC EDGAR | +1.72% | -1.44% | |
| MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes | Press release | GlobeNewswire | +4.88% | +5.16% | |
| MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval | Press release | GlobeNewswire | +0.65% | -1.70% | |
| Form 8-K MANNKIND CORP For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -2.80% | +1.96% | |
| MannKind to Present at Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -2.80% | +1.96% | |
| MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems | Press release | GlobeNewswire | -0.71% | +0.57% | |
| Form 8-K MANNKIND CORP For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +0.29% | +2.92% | |
| The $59B Quiet Shift Reshaping How Patients Access Care | Press release | Canada Newswire | -0.50% | -1.06% | |
| Form 10-Q MANNKIND CORP For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +7.70% | +7.25% | |
| Form 8-K MANNKIND CORP For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +7.70% | +7.25% | |
| MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases | Press release | GlobeNewswire | +22.58% | +4.40% | |
| MannKind Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +7.70% | +7.25% | |
| MannKind to Report First Quarter 2026 Financial Results on May 6, 2026 | Press release | GlobeNewswire | +2.00% | +2.91% | |
| Form ARS MANNKIND CORP For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.94% | -2.25% | |
| Form DEF 14A MANNKIND CORP For: Apr 07 | SEC filing · Form DEF | SEC EDGAR | -0.94% | -2.25% | |
| Form DEFA14A MANNKIND CORP | SEC filing · Form DEFA14A | SEC EDGAR | -0.94% | -2.25% | |
| MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 | Press release | GlobeNewswire | +0.38% | +2.68% | |
| MannKind Announces Settlement of Convertible Senior Notes | Press release | GlobeNewswire | -2.14% | -6.79% | |
| MannKind to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.02% | +0.00% | |
| Form 10-K MANNKIND CORP For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -6.22% | -12.43% | |
| Form 8-K MANNKIND CORP For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -6.22% | -12.43% | |
| MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -6.22% | -12.43% | |
| MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | -0.18% | +2.03% | |
| MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 | Press release | GlobeNewswire | -0.18% | -1.27% | |
| MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D) | Press release | GlobeNewswire | +1.65% | +2.78% | |
| MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy | Press release | GlobeNewswire | +0.18% | +2.20% | |
| Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets | Press release | GlobeNewswire | +0.09% | -3.62% | |
| MannKind Provides Business Updates and 2026 Growth Drivers | Press release | GlobeNewswire | +1.02% | +1.86% | |
| MannKind Shares FUROSCIX® Business Updates | Press release | GlobeNewswire | -0.50% | -0.84% | |
| Form 8-K/A MANNKIND CORP For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | +0.34% | -0.84% | |
| MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease | Press release | GlobeNewswire | +1.31% | +1.50% | |
| MannKind to Present at the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +1.53% | +0.19% | |
| Form 8-K MANNKIND CORP For: Nov 08 | SEC filing · Form 8-K | SEC EDGAR | +4.33% | +4.23% | |
| MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease | Press release | GlobeNewswire | +4.33% | +4.23% | |
| MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes | Press release | GlobeNewswire | -2.37% | -7.01% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MNKD section they belong to.
Where else MNKD is measured.
MNKD earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cellect Biotechnology Ltd. - American Depositary Shares (APOP) | 337 | -0.42% | 35% |
| Cardinal Health, Inc. (CAH) | 335 | +0.02% | 52% |
| Protagonist Therapeutics, Inc. (PTGX) | 335 | -0.24% | 43% |
| MYOS RENS TECH INC COMMON (MYOS) | 334 | 0.00% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is MannKind Corporation's median reaction calculated?
Every labeled MNKD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 335 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of MNKD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MNKD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.